Question 1

Which has better weight loss data, Zepbound or Foundayo?

Accepted Answer

Zepbound, by roughly a 2x margin. SURMOUNT-1 (Jastreboff 2022 NEJM, PMID 35658024) showed tirzepatide 15 mg cut body weight 20.9% at 72 weeks in adults with obesity. ATTAIN-1 (Wharton 2025 NEJM, PMID 40960239) showed orforglipron 17.2 mg cut body weight 11.2% at 72 weeks — also a real, clinically meaningful loss, but roughly half of Zepbound. The two drugs have not been compared head-to-head; cross-trial differences in population, baseline BMI, and lifestyle co-intervention apply, but the magnitude gap is large enough that the ranking is robust.

Question 2

Why would I pick the oral pill instead of the injection?

Accepted Answer

Three patient profiles: needle-averse patients (a significant minority refuse injections even after counseling), frequent travelers (an oral pill avoids cold-chain storage and TSA screening of injectable pens), and dose-flexibility seekers (a daily oral dose can be paused or resumed more responsively than a weekly subq with a 7+ day half-life). Foundayo also lacks the strict fasting protocol that Rybelsus (the older oral GLP-1) requires — take Foundayo with or without food, any time of day.

Question 3

Does Foundayo really work without food restrictions?

Accepted Answer

Yes — and this is the defining advantage over Rybelsus. Foundayo is a non-peptide small-molecule designed for oral absorption from the outset, so it does not require an empty stomach or a 30-minute post-dose fast. Lilly's pharmacokinetic studies showed bioavailability and exposure were not meaningfully affected by food (Ma 2024 Diabetes Ther; orforglipron PK was the original molecule's signature feature). ATTAIN-1 and ACHIEVE-1 protocols allowed dosing with food, and efficacy still hit pivotal endpoints. This is a real selling point for daily-adherence patients.

Question 4

Are both FDA-approved for weight loss?

Accepted Answer

Yes. Zepbound was FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27 with weight-related comorbidity) in November 2023, with an additional indication for moderate-to-severe obstructive sleep apnea added in December 2024 (Malhotra 2024 NEJM). Foundayo was FDA-approved in 2025 for both chronic weight management and type 2 diabetes based on the ATTAIN-1 and ACHIEVE-1 pivotal trials. Both are on-label for obesity prescribing — no off-label workaround needed for either.

Question 5

Which is cheaper?

Accepted Answer

Foundayo. Both are sold through LillyDirect self-pay. Zepbound vials or KwikPen run $299/mo (2.5 mg starter), $399/mo for 5 mg and $449/mo for higher doses on the refill program. Foundayo starts at $149/mo for 0.8 mg and 2.5 mg, $199/mo for 5.5 mg and $299/mo for 9 mg, with 14.5 mg and 17.2 mg at $299/mo when you refill within 45 days (the 2.5 mg and 5.5 mg prices are temporarily reduced through December 31, 2026). That is $150/mo less at the starting dose ($149 vs $299) and $150/mo less at the top doses ($299 vs $449). Both are branded specialty drugs without generics. Commercial insurance coverage is the larger variable: many plans now cover Zepbound for obesity, while Foundayo's formulary status is still being negotiated payer-by-payer through 2026.

Question 6

Can I switch between Zepbound and Foundayo?

Accepted Answer

Clinically, yes — different molecular classes (tirzepatide is a peptide dual agonist; orforglipron is a non-peptide GLP-1-only small molecule), so there is no dose-equivalence table. Standard practice when switching either direction is to stop the prior drug and restart the new one at its lowest titration dose (Zepbound 2.5 mg weekly, or Foundayo 3 mg daily), then titrate up every 4 weeks per the FDA label. Expect a brief GI tolerability period during re-titration. Most patients who switch from Zepbound to Foundayo do so because they cannot tolerate or cannot access injections — not because efficacy is equivalent (it is not).

Field	Zepbound	Foundayo
Route & frequency	Once-weekly subcutaneous injection (pen or vial)	Once-daily oral tablet
Mechanism	Dual GIP / GLP-1 receptor agonist (peptide)	GLP-1 receptor agonist (non-peptide small molecule)
Weight loss (pivotal obesity trial)	−20.9% TBWL / 72 wk (SURMOUNT-1, 15 mg)	−11.1% body weight / 72 wk (ATTAIN-1, 17.2 mg)
Head-to-head vs Wegovy	SURMOUNT-5: tirzepatide −20.2% vs semaglutide −13.7%	No head-to-head against tirzepatide published
FDA-approved indications	Chronic weight management (Nov 2023); obstructive sleep apnea (Dec 2024)	Type 2 diabetes (2025); chronic weight management (2025)
Dosing schedule	2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg once weekly subq	0.8 → 2.5 → 5.5 → 9 → 14.5 → 17.2 mg once daily oral
Food / timing restriction	None — inject any day, with or without food	None — take any time of day, with or without food (unlike Rybelsus)
Cash price (manufacturer)	$299-$449/mo via LillyDirect (vial or KwikPen, by dose)	$149-$299/mo via LillyDirect self-pay (by dose)
Cardiovascular outcome trial	SURPASS-CVOT readout pending 2027	Dedicated CV outcomes trial not yet published

Zepbound vs Foundayo (2026): Injectable vs Oral GLP-1 Verdict

The verdict

Side-by-side comparison

Frequently asked questions